# Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

> **NCT01532089** · PHASE2 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 88 (actual)

## Conditions studied

- EGFR Exon 19 Deletion Mutation
- EGFR NP_005219.2:p.L858R
- Lung Non-Squamous Non-Small Cell Carcinoma
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Erlotinib
- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01532089
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-16
- **Primary completion:** 2018-02-13
- **Final completion:** 2020-08-18
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2020-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532089, "Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01532089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*